JP2019508032A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508032A5 JP2019508032A5 JP2018539138A JP2018539138A JP2019508032A5 JP 2019508032 A5 JP2019508032 A5 JP 2019508032A5 JP 2018539138 A JP2018539138 A JP 2018539138A JP 2018539138 A JP2018539138 A JP 2018539138A JP 2019508032 A5 JP2019508032 A5 JP 2019508032A5
- Authority
- JP
- Japan
- Prior art keywords
- dcc
- somatic
- pharmaceutical composition
- cancerous disease
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000000392 somatic effect Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 16
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 12
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 12
- 210000000349 chromosome Anatomy 0.000 claims description 12
- 102100039788 GTPase NRas Human genes 0.000 claims description 8
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 8
- 210000001165 lymph node Anatomy 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- 210000001082 somatic cell Anatomy 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 208000015891 sexual disease Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 210000005005 sentinel lymph node Anatomy 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16152883.1A EP3199641B1 (en) | 2016-01-27 | 2016-01-27 | Means and methods for staging, typing and treating a cancerous disease |
| EP16152883.1 | 2016-01-27 | ||
| PCT/EP2017/051789 WO2017129753A1 (en) | 2016-01-27 | 2017-01-27 | Means and methods for staging, typing and treating a cancerous disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508032A JP2019508032A (ja) | 2019-03-28 |
| JP2019508032A5 true JP2019508032A5 (cg-RX-API-DMAC10.html) | 2020-03-05 |
Family
ID=55310656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539138A Pending JP2019508032A (ja) | 2016-01-27 | 2017-01-27 | がん性疾患をステージング、タイピングおよび処置するための手段および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11702701B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3199641B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2019508032A (cg-RX-API-DMAC10.html) |
| CN (1) | CN108770360B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017211976B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3012404A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2905208T3 (cg-RX-API-DMAC10.html) |
| SG (1) | SG11201805990XA (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017129753A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1109938T3 (da) | 1998-09-18 | 2002-05-27 | Micromet Ag | DNA-amplificering af en enkelt celle |
| AU2002216009A1 (en) * | 2000-11-03 | 2002-05-15 | Michael Giesing | Clinical and functional validation of targets from disseminated cancer cells |
| ITRM20110149A1 (it) * | 2011-03-25 | 2012-09-26 | Massimo Zollo | Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione. |
| WO2013009632A2 (en) * | 2011-07-08 | 2013-01-17 | The University Of Utah Research Foundation | Methods of detecting hereditary cancer predisposition |
| JP2015500035A (ja) * | 2011-12-10 | 2015-01-05 | アボツト・モレキユラー・インコーポレイテツド | 悪性黒色腫の診断および悪性黒色腫の転移の予後予測のための物質および方法 |
| EP3033150A4 (en) * | 2013-08-13 | 2017-06-28 | Bionumerik Pharmaceuticals, Inc. | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
| WO2015118077A1 (en) | 2014-02-05 | 2015-08-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Error-free sequencing of dna |
-
2016
- 2016-01-27 ES ES16152883T patent/ES2905208T3/es active Active
- 2016-01-27 EP EP16152883.1A patent/EP3199641B1/en active Active
-
2017
- 2017-01-27 AU AU2017211976A patent/AU2017211976B2/en active Active
- 2017-01-27 JP JP2018539138A patent/JP2019508032A/ja active Pending
- 2017-01-27 EP EP17706412.8A patent/EP3408411A1/en not_active Withdrawn
- 2017-01-27 US US16/073,271 patent/US11702701B2/en active Active
- 2017-01-27 WO PCT/EP2017/051789 patent/WO2017129753A1/en not_active Ceased
- 2017-01-27 SG SG11201805990XA patent/SG11201805990XA/en unknown
- 2017-01-27 CN CN201780008861.6A patent/CN108770360B/zh active Active
- 2017-01-27 CA CA3012404A patent/CA3012404A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wick et al. | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma | |
| Zhang et al. | Reduction sensitive polymers delivering Cationic platinum drugs as STING agonists for enhanced chemo‐immunotherapy | |
| Aung et al. | Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial | |
| Cho et al. | Nilotinib in patients with metastatic melanoma harboring KIT gene aberration | |
| JP2018508469A5 (cg-RX-API-DMAC10.html) | ||
| ES2686549T3 (es) | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer | |
| Youngblood et al. | Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells | |
| JP2018532736A5 (cg-RX-API-DMAC10.html) | ||
| JP2019532051A5 (cg-RX-API-DMAC10.html) | ||
| Jachowski et al. | Modern therapies of nonsmall cell lung cancer | |
| JP2016525097A5 (cg-RX-API-DMAC10.html) | ||
| JP2017513908A5 (cg-RX-API-DMAC10.html) | ||
| Lu et al. | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting | |
| US20210085745A1 (en) | Methods of identifying risk of bevacizumab-induced proteinuria and hypertension | |
| Remon et al. | How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review | |
| Sawamura et al. | Crizotinib-associated erythema multiforme in a lung cancer patient | |
| JP2020520923A5 (cg-RX-API-DMAC10.html) | ||
| Yang et al. | Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients | |
| Shen et al. | mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial | |
| Li et al. | The recent progress of tumor cell-derived exosomes in the pathogenesis, diagnosis and therapeutic strategies of tumors | |
| Li et al. | Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives | |
| JP2022540759A5 (cg-RX-API-DMAC10.html) | ||
| Andrews et al. | Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma | |
| Kenneth | Advances in systemic therapy in pancreatic cancer | |
| Flippot et al. | Management of metastatic renal cell carcinoma with variant histologies |